Liptruzet Approval History

• FDA approved: Yes (First approved May 3rd, 2013)
• Brand name: Liptruzet
• Generic name: atorvastatin and ezetimibe
• Company: Merck
• Treatment for: High Cholesterol, Familial Heterozygous

Liptruzet (atorvastatin and ezetimibe) is a statin (HMG-CoA reductase inhibitor) and cholesterol absorption inhibitor combination indicated for the treatment of hyperlipidemia.

FDA Approval History for Liptruzet

Date	Article
May  3, 2013	FDA Approves Merck’s Liptruzet (ezetimibe and atorvastatin), a New Product That Can Help Lower LDL Cholesterol
Jan  3, 2013	Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets

See also...

Liptruzet (atorvastatin and ezetimibe) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.